Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aflibercept + FOLFIRI in Metastatic Colorectal Cancer
NCT01882868Phase 2Completed
- Sponsor
- Sanofi
- Start
- Jul 2013
- Primary completion
- Aug 2015
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of aflibercept in colorectal cancer (metastatic) (mCRC), sponsored by Sanofi. Primary endpoint: Objective Response Rate. Started Jul 2013; status: completed.
02
Drugs
aflibercept
03
Conditions
colorectal cancer (metastatic) (mCRC)
Beyond the preview
Go deeper on NCT01882868.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01882868.